机构：[1]Department of Neurosurgery, Xiangya Hospital, Central South University,Changsha, Hunan, China.[2]XiangYa School of Medicine, Central South University, Changsha, Hunan, China.[3]National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.[4]Department of Neurosurgery, The Second Afliated Hospital, Chongqing Medical University,Chongqing, China.[5]Department of Psychiatry, The Second People’s Hospital of Hunan Province, The Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.[6]The School of Clinical Medicine,Hunan University of Chinese Medicine, Changsha, Hunan, China.[7]Department of Oncology, Xiangya Hospital, Central South University, Changsha,Hunan, China.[8]One-third Lab, College of Bioinformatics Science and Technology, Harbin Medical University,Harbin, Heilongjiang, China.[9]Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou,Guangdong, China.南方医科大学珠江医院[10]Department of Interventional Radiology, The First Afliated Hospital of Zhengzhou, Zhengzhou,Henan, China.[11]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells, and bypass tumor cell apoptosis avoidance mechanisms to some extent. This method has been extensively used to treat hematologic diseases, but the therapeutic effect in solid tumors is not ideal. Tumor antigen escape, treatment-related toxicity, and the immunosuppressive tumor microenvironment (TME) limit their use of it. Target selection is the most critical aspect in determining the prognosis of patients receiving this treatment. This review provides a comprehensive summary of all therapeutic targets used in the clinic or shown promising potential. We summarize CAR-T cell therapies' clinical trials, applications, research frontiers, and limitations in treating different cancers. We also explore coping strategies when encountering sub-optimal tumor-associated antigens (TAA) or TAA loss. Moreover, the importance of CAR-T cell therapy in cancer immunotherapy is emphasized.
基金：
This work was supported by the National Natural Science Foundation of China
(NO.82073893, 82172685, 81873635, 81703622). Hunan Provincial Natural
Science Foundation of China (NO. 2022JJ20095, 2018SK2101, 2018JJ3838),
China Postdoctoral Science Foundation (NO. 2018M633002), Hunan Provincial
Health Committee Foundation of China (NO. 202204044869).
第一作者机构：[1]Department of Neurosurgery, Xiangya Hospital, Central South University,Changsha, Hunan, China.[2]XiangYa School of Medicine, Central South University, Changsha, Hunan, China.[3]National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Neurosurgery, Xiangya Hospital, Central South University,Changsha, Hunan, China.[3]National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
推荐引用方式(GB/T 7714)：
Qu Chunrun,Zhang Hao,Cao Hui,et al.Tumor buster-where will the CAR-T cell therapy 'missile' go?[J].MOLECULAR CANCER.2022,21(1):doi:10.1186/s12943-022-01669-8.
APA：
Qu, Chunrun,Zhang, Hao,Cao, Hui,Tang, Lanhua,Mo, Haoyang...&Cheng, Quan.(2022).Tumor buster-where will the CAR-T cell therapy 'missile' go?.MOLECULAR CANCER,21,(1)
MLA：
Qu, Chunrun,et al."Tumor buster-where will the CAR-T cell therapy 'missile' go?".MOLECULAR CANCER 21..1(2022)
医学